{
    "nct_id": "NCT05879367",
    "official_title": "An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma",
    "inclusion_criteria": "* Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype per WHO 2021 tumor classification.\n* Completed external beam radiation therapy per standard of care.\n* Must have received at least 80% of planned daily doses of TMZ during chemoradiation.\n* Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.\n* Willing to abstain from intercourse or use acceptable contraceptive methods.\n* If taking corticosteroids, must be on a stable or decreasing dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recent history of recurrent or metastatic cancer that could confound response assessments\n* Prior systemic chemotherapy for GBM other than temozolomide during external beam radiation therapy.\n* Prior Optune treatment.\n* Active infection or serious intercurrent medical illness.\n* Poorly controlled seizures.\n* Significant cardiac disease within 6 months of enrollment.\n* Poorly controlled diabetes.\n* Use of another investigational agent within 30 days of enrollment.",
    "miscellaneous_criteria": ""
}